OCUGEN, INC. Finance Lease, Liability, Noncurrent
OCUGEN, INC. (OCGN) had Finance Lease, Liability, Noncurrent of $17.34 thousand as of 2019-09-30, per its 10-Q filed 2019-11-12.
Discontinued › Balance Sheet › Liabilities › Liabilities, Noncurrent › Long-Term Debt and Lease Obligation
us-gaap:FinanceLeaseLiabilityNoncurrent · last filed 2019-11-12
- 2019-09-30: Finance Lease, Liability, Noncurrent $17.34K.
- 2019-06-30: Finance Lease, Liability, Noncurrent $22.90K.
- 2018-12-31: Finance Lease, Liability, Noncurrent $33.72K.
| Period end | Finance Lease, Liability, Noncurrent |
|---|---|
| 2019-09-30 | $17.34K 10-Q · filed 2019-11-12 |
| 2019-06-30 | $22.90K 8-K/A · filed 2019-10-07 |
| 2018-12-31 | $33.72K 10-Q · filed 2019-11-12 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Cabaletta Bio, Inc. (CABA) | United States | $0.365B | -2.81 |
| Artiva Biotherapeutics, Inc. (ARTV) | United States | $0.367B | |
| FENNEC PHARMACEUTICALS INC. (FENC) | United States | $0.371B | -115.85 |
| C4 Therapeutics, Inc. (CCCC) | United States | $0.373B | -5.65 |
| Century Therapeutics, Inc. (IPSC) | United States | $0.306B | -4.02 |
| SAB Biotherapeutics, Inc. (SABS) | United States | $0.306B | -25.49 |
| AGENUS INC (AGEN) | United States | $0.383B | 1.41 |
| X4 Pharmaceuticals, Inc (XFOR) | United States | $0.297B | -4.99 |
| Inhibikase Therapeutics, Inc. (IKT) | United States | $0.296B | -4.44 |
| Surrozen, Inc./DE (SRZN) | United States | $0.395B |